Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a fourth-quarter 2013 loss of 32 cents per share (excluding one-time expenses), narrower than the year-ago loss of 43 cents per share and the Zacks Consensus Estimate of a loss of 40 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -6.08% in last session and finished the day at $1.70. Traded volume was 1.35million shares in the last session and … Continue reading Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

NASDAQ Losers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Himax Technologies, Inc. (NASDAQ:HIMX), Blue Earth Inc. (NASDAQ:BBLU), Omeros Corporation (NASDAQ:OMER), Net Element International Inc (NASDAQ:NETE)

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases, announced the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania (Penn); Inovio Pharmaceuticals; and MedImmune, the global biologics … Continue reading NASDAQ Losers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Himax Technologies, Inc. (NASDAQ:HIMX), Blue Earth Inc. (NASDAQ:BBLU), Omeros Corporation (NASDAQ:OMER), Net Element International Inc (NASDAQ:NETE)

In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares in the last session and the average volume of the … Continue reading Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation (NASDAQ:CELG) stock performance was 0.88% in last session and finished … Continue reading Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Hercules Offshore Inc (NASDAQ:HERO) Director Thomas R. Bates, Jr. purchased 20,000 shares of the stock on the open market in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average price of $3.93 per share, for a total transaction of $78,600.00. Following the completion of the transaction, the director now directly owns 280,000 shares in the company, valued at approximately … Continue reading Small Cap Insider Buying: Hercules Offshore (NASDAQ:HERO), Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros Corporation (NASDAQ:OMER), Insys (NASDAQ:INSY), New Mountain Finance (NYSE:NMFC)